Casgevy Therapy Revenue Shows Significant Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy CRSP?
Source: Benzinga
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
CRISPR Therapeutics Plans $350 Million Private Debt Offering
- Funding Initiative: CRISPR Therapeutics announced plans to raise $350 million through a private offering of convertible senior notes to support its gene-editing biotechnology research and development efforts, demonstrating the company's commitment to advancing innovative projects.
- Debt Structure: The debt securities will rank as senior unsecured obligations and are scheduled to mature in 2031, reflecting the company's financing strategy under current market conditions and investor demand.
- Market Reaction: Following the announcement of the funding plan, CRISPR Therapeutics' stock traded over 6% lower in Tuesday's premarket, indicating investor concerns about the company's future financial health, which may impact its short-term stock performance.
- R&D Support: By pursuing this debt financing, CRISPR aims to provide funding for further development of its gene-editing technologies, and despite facing market volatility, the company remains committed to driving breakthroughs in the biotechnology sector.
See More
CRISPR Therapeutics Plans $350 Million Convertible Notes Offering
- Financing Size: CRISPR Therapeutics AG announced its intention to offer $350 million in convertible senior notes through a private placement, which is expected to provide funding for general corporate purposes, although the market reacted negatively with an 8.23% drop in pre-market trading to $53.94.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, which may attract more investors and enhance the likelihood of successful financing.
- Debt Structure: The notes will be senior unsecured obligations maturing on March 1, 2031, with interest payable semiannually on March 1 and September 1, ensuring investors receive stable returns over the investment period.
- Market Impact: Despite the company's plans to enhance financial flexibility through this offering, the significant drop in stock price may reflect market concerns regarding its future growth potential, prompting investors to monitor subsequent market reactions and strategic adjustments.
See More
TD Cowen Upgrades Rivian to Buy, Raises Price Target
- Rating Upgrade: TD Cowen upgraded Rivian's stock from 'Hold' to 'Buy', indicating strong confidence in the electric vehicle maker's future performance, which is likely to attract more investor interest.
- Price Target Increase: The firm raised its price target on Rivian shares from $17 to $20, reflecting optimistic expectations regarding the potential demand for its upcoming R2 vehicle platform, which could significantly expand market reach.
- Positive Market Reaction: Following the upgrade, Rivian's stock traded over 4% higher in Tuesday's premarket, indicating market recognition of the company's growth prospects, which may further drive stock price increases.
- New Model Strategy: The R2 vehicle platform is seen as a crucial component of Rivian's strategic expansion, and if successfully launched, it will help enhance its position in the highly competitive electric vehicle market.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Vertex Pharmaceuticals Performance: Vertex Pharmaceuticals Inc. (VRTX) saw a 6.2% increase in pre-market trading.
- UFP Industries Performance: UFP Industries Inc. (UFPI) experienced a 5.0% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
CRISPR Therapeutics to Offer $350M Convertible Senior Notes
- Financing Plan: CRISPR Therapeutics plans to raise $350 million through a private offering of convertible senior notes, which is expected to enhance the company's financial flexibility for general corporate purposes.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, potentially increasing the total financing amount and boosting market confidence.
- Interest and Maturity: The notes will accrue interest payable semiannually and mature on March 1, 2031, providing long-term funding support unless converted, redeemed, or repurchased earlier.
- Stock Price Reaction: Following the financing announcement, CRSP shares fell 6.5% in premarket trading to $54.94, indicating market caution regarding the offering and potentially impacting investor sentiment.
See More
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
CRISPR Therapeutics Plans $350 Million Private Debt Offering
- Funding Initiative: CRISPR Therapeutics announced plans to raise $350 million through a private offering of convertible senior notes to support its gene-editing biotechnology research and development efforts, demonstrating the company's commitment to advancing innovative projects.
- Debt Structure: The debt securities will rank as senior unsecured obligations and are scheduled to mature in 2031, reflecting the company's financing strategy under current market conditions and investor demand.
- Market Reaction: Following the announcement of the funding plan, CRISPR Therapeutics' stock traded over 6% lower in Tuesday's premarket, indicating investor concerns about the company's future financial health, which may impact its short-term stock performance.
- R&D Support: By pursuing this debt financing, CRISPR aims to provide funding for further development of its gene-editing technologies, and despite facing market volatility, the company remains committed to driving breakthroughs in the biotechnology sector.
See More
CRISPR Therapeutics Plans $350 Million Convertible Notes Offering
- Financing Size: CRISPR Therapeutics AG announced its intention to offer $350 million in convertible senior notes through a private placement, which is expected to provide funding for general corporate purposes, although the market reacted negatively with an 8.23% drop in pre-market trading to $53.94.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, which may attract more investors and enhance the likelihood of successful financing.
- Debt Structure: The notes will be senior unsecured obligations maturing on March 1, 2031, with interest payable semiannually on March 1 and September 1, ensuring investors receive stable returns over the investment period.
- Market Impact: Despite the company's plans to enhance financial flexibility through this offering, the significant drop in stock price may reflect market concerns regarding its future growth potential, prompting investors to monitor subsequent market reactions and strategic adjustments.
See More
TD Cowen Upgrades Rivian to Buy, Raises Price Target
- Rating Upgrade: TD Cowen upgraded Rivian's stock from 'Hold' to 'Buy', indicating strong confidence in the electric vehicle maker's future performance, which is likely to attract more investor interest.
- Price Target Increase: The firm raised its price target on Rivian shares from $17 to $20, reflecting optimistic expectations regarding the potential demand for its upcoming R2 vehicle platform, which could significantly expand market reach.
- Positive Market Reaction: Following the upgrade, Rivian's stock traded over 4% higher in Tuesday's premarket, indicating market recognition of the company's growth prospects, which may further drive stock price increases.
- New Model Strategy: The R2 vehicle platform is seen as a crucial component of Rivian's strategic expansion, and if successfully launched, it will help enhance its position in the highly competitive electric vehicle market.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Vertex Pharmaceuticals Performance: Vertex Pharmaceuticals Inc. (VRTX) saw a 6.2% increase in pre-market trading.
- UFP Industries Performance: UFP Industries Inc. (UFPI) experienced a 5.0% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
CRISPR Therapeutics to Offer $350M Convertible Senior Notes
- Financing Plan: CRISPR Therapeutics plans to raise $350 million through a private offering of convertible senior notes, which is expected to enhance the company's financial flexibility for general corporate purposes.
- Additional Purchase Option: Initial purchasers will have a 13-day option to buy an additional $52.5 million of the notes, potentially increasing the total financing amount and boosting market confidence.
- Interest and Maturity: The notes will accrue interest payable semiannually and mature on March 1, 2031, providing long-term funding support unless converted, redeemed, or repurchased earlier.
- Stock Price Reaction: Following the financing announcement, CRSP shares fell 6.5% in premarket trading to $54.94, indicating market caution regarding the offering and potentially impacting investor sentiment.
See More
